Clinical Trials
70 trialsSUROVA
Clinica Universidad de Navarra, Universidad de Navarra
NEO
University Health Network, Toronto
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Guangxi Medical University
MIRRORS-RCTP
Royal Surrey County Hospital NHS Foundation Trust
AL3818
Advenchen Laboratories, LLC
BEACON
Peter MacCallum Cancer Centre, Australia
SELENIUM
Seoul National University Hospital
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Shanghai Yunying Medical Technology
Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer
Ruijin Hospital
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
GOGER-01
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
Yonsei University
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
HIPEC After Initial CRS in Patients Who Have Received NACT
Northwell Health
BriTROC-2
Cancer Research UK, Glasgow
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
OncXerna Theraputics, Inc.
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
Aivita Biomedical, Inc.
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
MITO 27
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
GOG Foundation
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
GOG Foundation
MITO25
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Shanghai Gynecologic Oncology Group
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Lee's Pharmaceutical Limited
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
University Hospital Southampton NHS Foundation Trust
AVANIRA3
Jiangsu Cancer Institute & Hospital
MIRRORS
Royal Surrey County Hospital NHS Foundation Trust
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Massachusetts General Hospital
BEDOCA
Sheba Medical Center
Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer
M.D. Anderson Cancer Center
ROCOCO
Seoul National University Hospital
EHTASEOCCS
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
OVANOX
Turku University Hospital
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Lee's Pharmaceutical Limited
HIPEC/IPHC
Bay Area Gynecology Oncology
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
GOG Foundation
COTI2-101
Critical Outcome Technologies Inc.
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
British Columbia Cancer Agency
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
National University Hospital, Singapore
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
ProlantaOC
Oncolix, Inc.
EHNPCTASEOC
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
CARCINOHIPEC
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Total/Subtotal Colectomy in Ovarian Cancer
Shanghai Gynecologic Oncology Group